TLR4 and diabetes mellitus: Intravitreal injections of anti-Il-1β and anti-Tlr4 neutralizing antibodies to animals with STZ-induced diabetes significantly reduced retinal Lgals1 expression (anti-Il-1β, fold change = 1.96; anti-Tlr4, fold change = 1.41) compared to normal IgG treatment (fold change = 3.55) (Fig. 6E).